|
⚲
|
| Keyboard |
| Ikarian Capital LLC
✚
|
|
|---|---|
| CRD # | 281880 |
| SEC # | 801-118894 |
| CIK # | 0001778253 |
| AUM | 698.0 M (2026-05-20) |
| Employees | 8 (38% Investors, 12% Brokers) |
| Fees | |
| Minimum | |
| Phone | 214-276-0670 |
| Address | 100 Crescent Court Dallas, TX 75201 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Cytokinetics Inc | 0.1 | ||
| Kodiak Sciences Inc | 0.1 | ||
| Abivax Sa | 0.0 | ||
| Alumis Inc | 0.0 | ||
| Bristol Myers Squibb Co | 0.0 | ||
| Nile Therapeutics Inc | 0.0 | ||
| Revolution Medicines Inc | 0.0 | ||
| Vaxcyte Inc | 0.0 | ||
| Praxis Precision Medicines Inc | 0.0 | ||
| Biosante Pharmaceuticals Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Ikarian Healthcare Master Fund LP | [2020-05-12] | 217.5 M | 564.0 M |
| Filed 2026-01-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 698.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 698.0 |
| By Discretionary | ||
| Discretionary | 5 | 698.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 698.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 597.1 | |
| United States Persons | 100.8 | |
| Total | 5 | 698.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Sophia Dilbert | Director | 109 | 44 | |
| Amber Ramsey | Director | 72 | 30 | |
| Joe Hardiman | Director | 12 | 6 | |
| Chart Westcott Living Trust | Executive Officer | 2 | 2 | |
| Chart Westcott | Director | 2 | 2 | |
| Ikarian Capital LLC | Executive Officer | 2 | 2 | |
| Neil Shahrestani | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001778253] | |
| 3 | [0001778253] | |
| 4 | [0001778253] | |
| SC 13G | [0001778253] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.6B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300NZUQ6FNNAIEE33 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Ikarian Capital LLC | |
| Ikarian Healthcare Fund GP LP | |
| Shahrestani Neil | |
| Chart Westcott Living Trust | |
| Ikarian Healthcare Master Fund LP | |
| Tracon Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-12-30 | Buy | 520,291 | $9.61 | 4,999,997 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-11-11 | Buy | 5,000 | $7.53 | 37,650 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-10-30 | Buy | 21,300 | $4.64 | 98,832 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-10-29 | Buy | 7,700 | $4.77 | 36,729 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-09-11 | Buy | 78,201 | $3.93 | 307,330 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-09-09 | Buy | 79,415 | $3.49 | 277,158 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-09-08 | Buy | 13,244 | $2.90 | 38,408 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock, par value $0.001 per share
|
2020-09-04 | Buy | 151,611 | $2.87 | 435,124 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Corrigo Investment Partners LLC
✚
|
TX | 707.2 M |
|
Marchant MC Limited
✚
|
705.1 M | |
|
Southeastern Asset Management International Singapore PTE Ltd
✚
|
702.7 M | |
|
Entrypoint Capital LLC
✚
|
NY | 700.3 M |
|
SW Investment Management LLC
✚
|
698.5 M | |
|
Fox Run Management LLC
✚
|
CT | 695.8 M |
|
Value Holdings Management Co LLC
✚
|
694.5 M | |
|
Blueshift Asset Management LLC
✚
|
NJ | 694.4 M |
|
Moneda USA Inc
✚
|
NY | 694.0 M |
|
Ramsey Quantitative Systems Inc
✚
|
KY | 691.4 M |